Who are Paclitaxel, Docetaxel, Irinotecan's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dose dense AC followed by T + trastuzumab, docetaxel and cisplatin, Ivermectin + colchicine, Placebo plus Docetaxel, Paclitaxel, Carboplatin, nab-paclitaxel，Cisplatin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/paclitaxel-docetaxel-irinotecan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Paclitaxel, Docetaxel, Irinotecan — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Paclitaxel, Docetaxel, Irinotecan (Paclitaxel, Docetaxel, Irinotecan) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Microtubule inhibitor. Area: Oncology.

phase 3 Microtubule inhibitor Microtubules Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Paclitaxel, Docetaxel, Irinotecan (Paclitaxel, Docetaxel, Irinotecan) — Shanghai Hengrui Pharmaceutical Co., Ltd.. Paclitaxel, Docetaxel, and Irinotecan are microtubule inhibitors that work by stabilizing microtubules, thereby inhibiting cell division.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Paclitaxel, Docetaxel, Irinotecan TARGET	Paclitaxel, Docetaxel, Irinotecan	Shanghai Hengrui Pharmaceutical Co., Ltd.	phase 3	Microtubule inhibitor	Microtubules
Dose dense AC followed by T + trastuzumab	Dose dense AC followed by T + trastuzumab	Agendia	marketed	Chemotherapy regimen with monoclonal antibody	HER2 receptor (trastuzumab component); DNA/microtubules (chemotherapy components)
docetaxel and cisplatin	docetaxel and cisplatin	Sanofi	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (docetaxel); DNA (cisplatin)
Ivermectin + colchicine	Ivermectin + colchicine	Ain Shams University	marketed	Antiparasitic + anti-inflammatory combination	Glutamate-gated chloride channels (ivermectin); tubulin/microtubules (colchicine)
Placebo plus Docetaxel	Placebo plus Docetaxel	Infinity Pharmaceuticals, Inc.	marketed	Taxane (microtubule stabilizer)	Microtubules (β-tubulin)
Paclitaxel, Carboplatin	Paclitaxel, Carboplatin	Queensland Centre for Gynaecological Cancer	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (paclitaxel); DNA (carboplatin)
nab-paclitaxel，Cisplatin	nab-paclitaxel，Cisplatin	Yang Jianjun, PhD	marketed	Chemotherapy combination (taxane + platinum agent)	Microtubules (paclitaxel); DNA (cisplatin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Microtubule inhibitor class)

Ma Fei，MD · 2 drugs in this class
Eisai Co., Ltd. · 1 drug in this class
Jiangsu Alphamab Biopharmaceuticals Co., Ltd · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Nippon Kayaku Co., Ltd. · 1 drug in this class
Shanghai Hengrui Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Paclitaxel, Docetaxel, Irinotecan — Competitive Intelligence Brief. https://druglandscape.com/ci/paclitaxel-docetaxel-irinotecan. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab